Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1974 Jan;5(1):75–81. doi: 10.1128/aac.5.1.75

Clinical Study of the Use of the New Aminoglycoside Tobramycin for Therapy of Infections Due to Gram-Negative Bacteria

Gabriel Jaffe 1, William Ravreby 1, Burt R Meyers 1, Shalom Z Hirschman 1
PMCID: PMC428921  PMID: 4599125

Abstract

Tobramycin, a new aminoglycoside antimicrobial, was evaluated as therapy for infections due to gram-negative bacilli in 15 seriously ill patients with underlying diseases. Three of 10 patients with gram-negative bacteremias also had urinary tract infections. Two patients had respiratory tract infections, one had cellulitis, one had a urinary tract infection, and another had septic phlebitis. Twelve patients were cured of their infections. Eosinophilia was observed in one patient and another developed superinfection with Staphylococcus aureus after 6 days of tobramycin therapy. There were five isolates of Escherichia coli, five of Klebsiella sp., two of Pseudomonas sp., and one each of Enterobacter agglomerans, Serratia marcescens, and Enterobacter cloacae. The average serum concentration of tobramycin 2 h after a parenteral dose of 1.0 to 1.5 mg/kg was 5.1 μg/ml; higher concentrations of tobramycin were present in urine. Tobramycin proved to be an effective antimicrobial in these patients.

Full text

PDF
75

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altemeier W. A., Todd J. C., Inge W. W. Gram-negative septicemia: a growing threat. Ann Surg. 1967 Oct;166(4):530–542. doi: 10.1097/00000658-196710000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bryant R. E., Hood A. F., Hood C. E., Koenig M. G. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med. 1971 Jan;127(1):120–128. [PubMed] [Google Scholar]
  3. Crowe C. C., Sanders E. Is there complete cross-resistance of gram-negative bacilli to gentamicin and tobramycin? Antimicrob Agents Chemother. 1972 Nov;2(5):415–416. doi: 10.1128/aac.2.5.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Del Bene V. E., Farrar W. E., Jr Tobramycin: in vitro activity and comparison with kanamycin and gentamicin. Antimicrob Agents Chemother. 1972 Apr;1(4):340–342. doi: 10.1128/aac.1.4.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dienstag J., Neu H. C. In vitro studies of tobramycin, an aminoglycoside antibiotic. Antimicrob Agents Chemother. 1972 Jan;1(1):41–45. doi: 10.1128/aac.1.1.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. FINLAND M., JONES W. F., Jr, BARNES M. W. Occurrence of serious bacterial infections since introduction of antibacterial agents. J Am Med Assoc. 1959 Aug 29;170:2188–2197. doi: 10.1001/jama.1959.63010180008012. [DOI] [PubMed] [Google Scholar]
  7. Freid M. A., Vosti K. L. The importance of underlying disease in patients with gram-negative bacteremia. Arch Intern Med. 1968 May;121(5):418–423. [PubMed] [Google Scholar]
  8. Hodgin U. G., Sanford J. P. Gram-negative rod bacteremia. An analysis of 100 patients. Am J Med. 1965 Dec;39(6):952–960. doi: 10.1016/0002-9343(65)90118-x. [DOI] [PubMed] [Google Scholar]
  9. Martin C. M., Cuomo A. J., Geraghty M. J., Zager J. R., Mandes T. C. Gram-negative rod bacteremia. J Infect Dis. 1969 Apr-May;119(4):506–517. doi: 10.1093/infdis/119.4-5.506. [DOI] [PubMed] [Google Scholar]
  10. McHenry M. C., Gavan T. L., Gifford R. W., Jr, Geurkink N. A., Van Ommen R. A., Town M. A., Wagner J. G. Gentamicin dosages for renal insufficiency. Adjustments based on endogenous creatinine clearance and serum creatinine concentration. Ann Intern Med. 1971 Feb;74(2):192–197. doi: 10.7326/0003-4819-74-2-192. [DOI] [PubMed] [Google Scholar]
  11. Meyers B. R., Hirschman S. Z. Pharmacologic studies on tobramycin and comparison with gentamicin. J Clin Pharmacol New Drugs. 1972 Aug-Sep;12(8):321–324. doi: 10.1002/j.1552-4604.1972.tb00174.x. [DOI] [PubMed] [Google Scholar]
  12. Meyers B. R., Hirschman S. Z. Tobramycin: in vitro antibacterial spectrum of a new aminoglycoside. J Clin Pharmacol New Drugs. 1972 Aug-Sep;12(8):313–320. doi: 10.1002/j.1552-4604.1972.tb00173.x. [DOI] [PubMed] [Google Scholar]
  13. Moellering R. C., Jr, Wennersten C., Weinstein A. J. Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin. Antimicrob Agents Chemother. 1973 Apr;3(4):526–529. doi: 10.1128/aac.3.4.526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Naber K. G., Westenfelder S. R., Madsen P. O. Pharmacokinetics of the aminoglycoside antibiotic tobramycin in humans. Antimicrob Agents Chemother. 1973 Apr;3(4):469–473. doi: 10.1128/aac.3.4.469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. REAM C. R. RESPIRATORY AND CARDIAC ARREST AFTER INTRAVENOUS ADMINISTRATION OF KANAMYCIN WITH REVERSAL OF TOXIC EFFECTS BY NEOSTIGMINE. Ann Intern Med. 1963 Sep;59:384–387. doi: 10.7326/0003-4819-59-3-384. [DOI] [PubMed] [Google Scholar]
  16. Riff L. J., Jackson G. G. Pharmacology of gentamicin in man. J Infect Dis. 1971 Dec;124 (Suppl):S98–105. doi: 10.1093/infdis/124.supplement_1.s98. [DOI] [PubMed] [Google Scholar]
  17. Shimizu K. Clinical experience with gentamicin in Japan. J Infect Dis. 1969 Apr-May;119(4):448–452. doi: 10.1093/infdis/119.4-5.448. [DOI] [PubMed] [Google Scholar]
  18. Simon V. K., Mösinger E. U., Malerczy V. Pharmacokinetic studies of tobramycin and gentamicin. Antimicrob Agents Chemother. 1973 Apr;3(4):445–450. doi: 10.1128/aac.3.4.445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. YOW E. M. Clinical significance of rising incidence of infections due to gram-negative bacilli. Postgrad Med. 1955 May;17(5):413–419. doi: 10.1080/00325481.1955.11708216. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES